共 114 条
[21]
DiNardo CD(2021)Re: International system for human cytogenetic or cytogenomic nomenclature (ISCN): some thoughts, by T. Liehr Cytogenet Genome Res 381 1728-2499
[22]
Lachowiez CA(2016)Chemotherapy versus hypomethylating agents for the treatment of relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplant Biol Blood Marrow Transplant 3 4326-5823
[23]
Takahashi K(2019)Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML N Engl J Med 127 2489-1926
[24]
Döhner H(2021)Venetoclax-based regimens for relapsed/refractory acute myeloid leukemia in a real-life setting: a retrospective single-center experience J Clin Med 116 5818-245
[25]
Estey E(2019)Venetoclax for AML: changing the treatment paradigm Blood Adv 32 1919-1046
[26]
Grimwade D(2021)Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia Cancer 10 562558-932
[27]
Dombret H(2010)Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy Blood 103 237-e231
[28]
Seymour JF(2014)International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia J Clin Oncol 106 1034-2145
[29]
Butrym A(2020)Venetoclax-based combinations in acute myeloid leukemia: current evidence and future directions Front Oncol 2 923-2919
[30]
Gale RP(2018)Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the chronic malignancies working party of the European society of blood and marrow transplantation Haematologica 105 e228-839